{"id":"62704d3527e7","type":"article","url":"https://hartvaat.nl/2019/05/01/inflammatiemarkers-en-risico-op-hypertensie-meta-analyse-van-cohortstudies/","title":"Inflammatiemarkers en risico op hypertensie: meta-analyse van cohortstudies","title_en":"Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair","hs-crp","inflammatie"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2018-314216","source_url":"https://doi.org/10.1136/heartjnl-2018-314216","authors":["Ahmad Jayedi","Kazem Rahimi","Leonelo E Bautista","Milad Nazarzadeh","Mahdieh Sadat Zargar","Sakineh Shab-Bidar"],"significance":7,"published":"2019-05-01","source_date":"2019-05-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This meta-analysis of cohort studies showed that elevated inflammatory markers (CRP, IL-6, TNF-α) are independently associated with the future development of hypertension, establishing inflammation as a potential modifiable pathway in blood pressure elevation.","created":"2026-07-03T10:27:54Z","updated":"2026-07-03T13:27:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Meta-analyse die het verband onderzocht tussen inflammatiemarkers en het risico op het ontwikkelen van hypertensie. Inflammatie als oorzakelijke factor.","abstract_original":"OBJECTIVE: To systematically assess the association of circulating inflammation markers with the future risk of hypertension. METHODS: We did a systematic literature search of PubMed and Scopus, from database inception to July 10, 2018. Prospective and retrospective cohort studies evaluating the association of circulating C reactive protein (CRP), high-sensitive CRP (hs-CRP), interleukin 6 (IL-6) and IL-1β to the risk of developing hypertension in the general population were included. The relative risks (RRs) for the top versus bottom tertiles of circulating biomarkers were calculated using a fixed-effects/random-effects model. A potential non-linear dose-response association was tested. RESULTS: Fourteen prospective cohort studies, two retrospective cohort studies and five nested case-control studies involving 142 640 participants and 20 676 cases were identified. The RR for the third versus first tertiles of circulating CRP was 1.23 (95% CI 1.11 to 1.35; I2=59%, n=12). The association remained unchanged after adjustment for body mass index. The RRs for other biomarkers were as follows: hs-CRP (RR 1.20, 95% CI 1.02 to 1.37; I2=74%, n=7), IL-6 (RR 1.51, 95% CI 1.30 to 1.71; I2=0%, n=5), and IL-1β (RR 1.22, 95% CI 0.92 to 1.51; I2=0%, n=3). A non-linear dose-response meta-analysis demonstrated that the risk of hypertension increased linearly with increasing circulating inflammation markers, even within the low-risk and intermediate-risk categories. CONCLUSIONS: Higher levels of circulating CRP, hs-CRP and IL-6, but not IL-1β, were associated with the risk of developing hypertension. The association persisted in subgroups of studies defined by major sources of heterogeneity."}